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Introduction
The dominant catalytic approaches towards obtaining enantio-
merically pure compounds are homogeneous catalysis, which
includes transition metal catalysis,[1] organocatalysis,[2] and bio-
catalysis.[3] Until recently, these approaches to catalysis have
developed in parallel as separate fields. Over the last decade,
however, significant efforts have been made to bridge the gap
between these fields, resulting in artificial metalloenzymes.[4,5]
These are hybrid catalysts in which a catalytically active
transition metal complex is incorporated into a host biomacro-
molecule, typically a protein[6] or DNA.[7,8] The incentives for
the creation of artificial metalloenzymes are both practical and
fundamental. It is envisioned that artificial metalloenzymes can
combine the best of both worlds, that is, broad catalytic
scope, a hallmark of homogeneous catalysis, and high activity
and selectivity under mild conditions, which typically charac-
terize enzymatic catalysis. The creation of active and selective
artificial metalloenzymes is fundamentally important as it holds
important lessons for catalyst design and catalytic reaction
mechanisms in general.
The catalytic activity and selectivity of conventional
transition metal catalysts are almost exclusively controlled by
the first coordination sphere provided by the chelating ligand.
The dominant strategy towards achieving enantioselectivity
involves forcing an incoming reagent to approach selectively
from one prochiral side of a substrate, by sterically blocking
the other side.
In contrast, in enzymatic catalysis the second coordination
sphere, which is the term used for the combination of interac-
tions provided by the biomolecular scaffold, such as hydrogen
bonding and hydrophobic interactions, is an important con-
tributor to the catalytic activity and selectivity. It is usually the
second coordination sphere that is responsible for chiral
discrimination; it can induce selectivity in catalyzed reactions
by structurally complementing the transition state towards
one enantiomer of the product and/or directing a chemical
reactant to one prochiral face of a bound substrate. Artificial
metalloenzymes aim at harnessing second coordination sphere
interactions to create transition metal complexes that
display enzyme-like activities and selectivities.
In the present Review, the various approaches that can be
followed for the design and optimization of an artificial
metalloenzyme are described. An overview of the synthetic
transformations that have been achieved using artificial
metalloenzymes is provided, with a particular focus on recent
developments. Finally, the lessons learned from artificial metal-
loenzymes, in particular about the role of the second coordina-
tion sphere, and their potential for synthetic applications are
discussed.
1. Design of Artificial Metalloenzymes
Ideally, an artificial metalloenzyme would be designed de novo
from the 20 natural amino acids. The de novo design of a
metalloprotein is based on the construction of a polypeptide
sequence which is not directly correlated to any natural pro-
tein and that can fold in a well-defined three-dimensional
structure capable of binding metal ions. This would allow all
the structural features required to achieve highly active and
enantioselective catalysis to be included, from the start.
Examples of this approach include the de novo design of a
helical bundles, a common scaffold for several artificial heme
proteins.[9] Significant advances have been made in the com-
putational methods that are required for this purpose and re-
cently some successful examples of de novo designed enzymes
have been reported.[10,11] However, our understanding of
protein folding is still far from sufficient to allow the
routine design of novel enzymes for any desired synthetic
transformation.
For this reason, the design of artificial metalloenzymes has
focused on the creation of active sites in existing, native, bio-
molecular scaffolds, such as proteins and DNA. The design of
active sites into native scaffolds offers more choices and it is,
in principle, simpler than de novo design considering that
most native scaffolds already have sufficient thermodynamic
stability and tolerance for mutations. Furthermore, structural
information for most of the scaffolds used to date is available,
facilitating the design and optimization process considerably.
The three key parameters in the design of an artificial metal-
loenzyme are the transition metal catalyst, the biomolecular
scaffold, and the mode of attachment of the transition metal
catalyst to the scaffold. The choice of the transition metal cata-
lyst is principally guided by the catalytic activity that is desired.
[a] F. Rosati, Dr. G. Roelfes
Stratingh Institute for Chemistry, University of Groningen




Artificial metalloenzymes have emerged as a promising
approach to merge the attractive properties of homogeneous
catalysis and biocatalysis. The activity and selectivity, including
enantioselectivity, of natural metalloenzymes are due to the
second coordination sphere interactions provided by the
protein. Artificial metalloenzymes aim at harnessing second
coordination sphere interactions to create transition metal
complexes that display enzyme-like activities and selectivities.
In this Review, the various approaches that can be followed for
the design and optimization of an artificial metalloenzyme are
discussed. An overview of the synthetic transformations that
have been achieved using artificial metalloenzymes is provid-
ed, with a particular focus on recent developments. Finally, the
role that the second coordination sphere plays in artificial
metalloenzymes and their potential for synthetic applications
are evaluated.
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An important consideration is that the reactivity of the transi-
tion metal catalyst needs to be orthogonal to the biomolecular
scaffold, that is, it should be inert to the chemical functionali-
ties presented by the biomolecule. Furthermore, the catalyst
should be tolerant to water, as the use of artificial metallo-
enzymes implies working in aqueous solutions. The factors
involved in the selection of the biomolecular scaffold and the
mode of attachment of the catalyst are discussed below.
1.1. Selection of biomolecular scaffolds
Important considerations in the selection of biomolecular
scaffolds are their chemical properties, such as the overall
charge, pH and temperature stability, and tolerance to organic
solvents. Another important choice is whether to use a protein
or nucleotide scaffold. Both have been used with considerable
success and the catalytic scope of protein and DNA-based
artificial metalloenzymes reported to date is mostly comple-
mentary, as discussed later. The choice for protein or DNA has
consequences for the transition metal catalyst and the catalytic
chemistry that can be used. For example, whereas catalytic
oxidation is one of the most explored reaction types with
protein-based artificial metalloenzymes, complications can be
expected when using a DNA scaffold, due to its susceptibility
to undergo oxidative DNA strand scission.[12]
In addition to the chemical properties of the scaffold, funda-
mental choices about the design approach need to be made.
An artificial metalloenzyme can be based on a scaffold that
comprises an existing active site and/or binding pocket, which
can be reengineered, or alternatively, a new active site can be
created in a native biomolecular scaffold.
Using an existing active site or binding pocket is attractive
because the second coordination sphere, in principle, is al-
ready setup and after the initial design, it can be re-engineered
to optimize the performance of the catalyst. This approach
was followed in the seminal report of an artificial metalloen-
zyme by Wilson and Whitesides.[13] The protein avidin was used
as the biomolecular scaffold. This protein, which has an excep-
tionally strong affinity for biotin, contains a very large and
deep binding pocket that can accommodate both the catalyst
and the substrates. The choice of biomolecular scaffolds that
can be used, however, is limited since the binding pocket has
to be sufficiently large enough to accommodate both the tran-
sition metal catalyst and the substrates. The scaffolds that
have been used up to date to achieve enantioselective cataly-
sis with considerable success are proteins such as avidin
(Av),[13] streptavidin (Sav),[14] bovine serum albumin (BSA),[15]
and apo-myoglobin (apo-Mb).[16] Examples of other scaffolds
that have been investigated or proposed include papain,[17, 18]
cutinase,[19] carbonic anhydrase,[20] and tHisf.[21]
The alternative is to create a new active site in an existing
biomolecular scaffold that does not yet possess a binding
pocket. The advantage of this approach is that it greatly ex-
pands the number of scaffolds that can be used. However, a
priori, it is not clear how incorporation of a novel active site
will affect the structure and stability of the biomolecular
scaffold, as it may result in disruption of some important
intra- and intermolecular interactions.
A key example of the second approach is the DNA-based
asymmetric catalysis concept, introduced by Roelfes and Ferin-
ga.[22] In this approach, an active site is created in or near the
DNA groove by binding of a transition metal complex to DNA.
The second chiral coordination sphere provided by the DNA
directs the reaction towards one of the enantiomers of the
product, resulting in an enantiomeric excess. Another scaffold
that has been used for this approach is the peptide hormone
bovine pancreatic polypeptide (bPP).[23]
A special category consists of the proteins that present a
large vacant space, such as the iron storage protein ferritin.[24]
In addition to binding of transition metal complexes, the large
space available in these protein cages also allows for incorpo-
ration of metallic nanoparticles. These protein encapsulated
nanoparticles have mainly been investigated for their material
properties.[24,25] However, catalytic applications have been ex-
plored as well.[24] In these approaches, the role of the biomo-
lecular scaffold is different from the artificial metalloenzymes
above and not necessarily intended to achieve enantiomeric
excess. Rather, the scaffold acts as a container and/or reactor
to grow nanoparticles of a certain size and shape, which may
be important for catalysis. Moreover, the pores of the protein
cage can be used to discriminate substrates based on their
shape and size.[26]
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nologies under the guidance of Prof.
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1.2. Anchoring strategies
To ensure the localization of the metal containing moiety into
the host, two common strategies are used: noncovalent, which
include anchoring through supramolecular and dative
interactions, and covalent anchoring (Figure 1).[6]
The supramolecular approach makes use of the strong and
highly specific covalent interactions between biopolymers and
small molecules, such as ligands/inhibitors to generate artificial
enzymes. The above mentioned examples of artificial
metalloenzymes based on the biotin/(strept)avidin interaction
and DNA-based asymmetric catalysis involve supramolecular
anchoring. The success of this approach is related to the ease
of self-assembly of these artificial metalloenzymes, which
allows for rapid optimization. A potential complication is that
there may be some ambiguity about where the catalyst might
bind, depending on the strength and selectivity of the supra-
molecular interactions. As a result, the structure of the active
site may be less well-defined. As the example of DNA-based
asymmetric catalysis shows, such an approach can also give
rise to a very heterogeneous catalytic system in which every
catalytic site is in a different microenvironment, and hence, dis-
plays different activity and selectivity.[27] In contrast, the biotin/
streptavidin interaction is so strong that it will give rise to a
single species, which can be characterized structurally.[28]
A closely related anchoring approach involves dative bonds,
such as coordinative bonds between the catalytic metal ion
and functionalities presented by the biomolecular scaffold.
Examples include artificial metalloenzymes assembled from
Mn–salen complexes in myoglobin and Fe and Mn corroles in
serum albumins, which have been used in catalytic enantio-
selective sulfoxidation reactions.[16,29] In addition to the dative
bond, other supramolecular interactions are likely to be in-
volved as well. An added advantage of this approach is that
the dative bond allows for precise positioning of the transition
metal catalyst in the biomolecular scaffold.
The covalent anchoring approach builds on the seminal
work of Kaiser and involves the covalent incorporation of a
transition metal complex via the ligand to a predetermined po-
sition in a biomolecular scaffold.[30] In case of proteins, often a
cysteine residue is used as the anchoring site. This allows for
highly regio- and site-selective anchoring of the catalytic
moiety, with control over the structure and geometry of the
catalytic site. A considerable drawback is that the optimization
and redesign is not straightforward and is time-consuming,
involving chemical modification and non-trivial purification
steps. For this reason, highly efficient and chemoselective
conjugation reactions are desirable.
2. Tools for Optimization
An attractive feature of artificial metalloenzymes is that the
chemical catalyst and the biomolecular scaffold can be opti-
mized independently, followed by screening of all combina-
tions in a matrix format, if desired. This has been referred to as
the chemogenetic approach.[31] Combinatorial approaches in
combination with high-throughput screening are desirable.
The chemical catalyst is generally optimized by rational
design, preferably based on structural information for the
artificial metalloenzyme as a whole. Compared to traditional
transition metal catalysis, the advantage is that the ligand in
most instances is not chiral, which reduces the synthetic
complexity of the optimization process.
Optimization of the scaffold can be achieved by rational
design and design in combination with evolutionary
approaches, such as designed and directed evolution. The
different possible approaches to rationally (re)design a metal-
binding site in a protein have been recently summarized by Lu
et al : 1) the empirical approach. This includes the design by in-
spection, homology, and by replacement of modular units ;
2) the theoretical approach that uses computer search
algorithms that make predictions and help design a new active
site into a native scaffold by finding the optimal locations for
ligands; 3) semitheoretical approach that combines visual
inspection of proteins to identify optimal locations for ligands
to create a new metal-binding site and computer program
evaluation for the energetics of positioning appropriate amino
acid residues.[32]
Impressive demonstrations of rational redesign of metalloen-
zymes were recently reported by the group of Lu. In the first
example, the redox potential of a single curpredoxin was
tuned by judicious replacement of amino acid residues in the
second coordination sphere.[33] These residues were selected
based on structural information of the enzyme. In this manner
the hydrophobicity and hydrogen bonding of the second coor-
dination sphere were modulated such that the entire range of
redox potentials that is known for the family of cupredoxins
could be accessed by a single cupredoxin, without significant
structural change in the first coordination sphere. Moreover, it
was shown that the effect of mutations was additive, which
means that the redox potential can be tuned in a predictable
manner.
In another contribution, myoglobin (Mb) was re-designed
into a functional nitric oxide reductase, by creation of a novel
non-heme iron binding site in the distal pocket of Mb.[34] The
design was based on the X-ray structure of Fe-Mb in combina-
tion with a minimized computer model. The X-ray structure of
the rationally designed enzyme overlaid closely with the
minimized computer model, confirming the accuracy of the
predicted structure.
Figure 1. Representation of the concept of artificial metalloenzymes and the
various anchoring strategies: a) supramolecular, b) dative, and c) covalent. M
denotes the catalytically active transition metal.
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In evolutionary approaches, several parameters are varied
randomly to generate a library of variants that are then
screened for the desired catalytic activity. Designed evolution
is guided by structural information of the artificial metalloen-
zyme or the apo-scaffold and involves identification of critical
residues, which are then subjected to saturation mutagenesis,
either consecutively or simultaneously, to generate a small
sized library that is then screened for the desired catalytic
activity.[35]
In directed evolution, in principle, structural information is
not required. By introducing random mutations, for example
by error prone PCR, a library of artificial metalloenzymes can
be created.[4,36] Screening and selection of the most active or
selective variants is followed by more rounds of randomization
and selection, until the desired activity and selectivity have
been achieved.
The advantage, in principle, is that also positions remote
from the active site are probed. It has been shown on more
than one occasion that subtle changes remote from the cata-
lytic site had a dramatic effect on catalyst activity. Challenges
that need to be addressed include that with increasing library
size, the project becomes increasingly dependent on high
throughput methodologies. Moreover, directed evolution
approaches also require highly efficient and chemoselective
anchoring of the transition metal complexes, since intermedi-
ate purification steps should be avoided. In this regard, supra-
molecular anchoring approaches are particularly attractive. Fi-
nally, the quality of the library, that is, the degree of catalyst
improvement and the number of hits, can be disappointing.
Therefore a variety of other more focused library techniques
have been introduced, most notably the combinatorial active-
site saturation test (CAST), which is directed at the amino acids
directly associated with the active site. Reetz et al. demonstrat-
ed the potential of the CAST methodology for optimization of
an artificial metalloenzyme based on a biotin linked rhodium
diphosphine complex that was anchored to streptavidin. In
three rounds, the enantioselectivity was increased from 23 to
65% ee.[37]
3. Catalytic Scope of Artificial Metalloenzymes
The catalytic scope of artificial metalloenzymes to date is
already quite broad. An overview of the main classes of
reactions catalyzed by artificial metalloenzyme is provided.
This Review focuses on the key examples for every reaction
class, supplemented with the most recent developments. For a
comprehensive overview of all the reactions catalyzed by
artificial metalloenzymes up until 2008, a number of reviews
are available.[6, 24,31, 38,39]
3.1. Reductions
Artificial metalloenzymes for catalytic enantioselective hydro-
genations constitute some of the early successes for this field.
This is the class of reactions that was studied in the seminal
report of an artificial metalloenzyme by Wilson and White-
sides.[13] A rhodium phosphine complex was incorporated into
the binding pocket of avidin by a biotin moiety that was at-
tached covalently to the ligand. The resulting artificial rhodium
enzyme gave rise to a modest enantioselectivity of 41% ee in
catalytic asymmetric hydrogenation (Scheme 1).
The design was later matured by Ward and co-workers.[14, 40]
It was found that the best results were obtained by switching
to streptavidin. This improvement was attributed to streptavi-
din possessing a deeper binding pocket compared to avidin.
By using a chemogenetic approach, the design was further
improved. Firstly, the design of the ligand was optimized by
changing the spacer between the ligand for Rh and the biotin.
Then mutation of various residues close to the binding site by
glycine, resulted in the discovery of a mutant, S112G, which in
combination with the Rh complex gave rise to 96% ee in the
hydrogenation of acetamidoacrylic acid. Further chemogenetic
optimization, which included saturation mutagenesis at
position S112 of streptavidin, afforded a second generation of
artificial metalloenzymes, in which >95% ee of both enantio-
mers could be obtained. Catalytic hydrogenation has also
been achieved with biomolecular scaffolds such as papain[17]
and antibodies.[41]
Encapsulation of Pd nanoparticles in an apo-ferritin cage
provided an artificial metalloenzyme capable of catalyzing
hydrogenation of acrylamide substrates (Scheme 2).[26] No
enantioselectivity was observed, but the observed turnover
numbers did depend strongly on the size of the substrate,
with larger substrates reacting less efficiently. This was related
to the dimensions of the pores of the protein cage; larger sub-
strates diffuse less efficiently through the pores to the inside
of the cage, where the catalyst resides. As a result, a lower
Scheme 1. Catalytic enantioselective hydrogenation by artificial rhodium
enzymes based on avidin and streptavidin.
Scheme 2. Hydrogenation catalyzed by Pd nanoparticles encapsulated in
ferritin.
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reactivity is detected. By encapsulation of Au/Pd core-shell
nanoparticles in the protein cage, the reactivity of the artificial
metalloenzyme in catalytic hydrogenation of acrylamide was
further increased up to fourfold.[42]
Recently, stereoselective hydrogenation of olefins by Rh sub-
stituted carbonic anyhydrases was reported.[43] Replacement of
the Zn2+ from the active site in bovine carbonic anhydrase iso-
enzyme II by Rh, using [Rh(cod)2)]BF4, resulted in an artificial
enzyme capable of catalytic hydrogenation. This artificial met-
alloenzyme hydrogenated Z-stilbene 20 times more efficiently
than E-stilbene. In contrast, in the absence of the biomolecular
scaffold, E and Z stilbene were hydrogenated by the Rh com-
plex almost equally efficiently. A preliminary modeling study
suggested that this stereoselectivity was due to the better
compatibility of Z-stilbene with the structure of the active site.
Artificial ruthenium enzymes for catalytic enantioselective
transfer hydrogenation of ketones have been developed
using the biotin/(strept)avidin concept (Scheme 3). [h6-p-
cymene)Ru(ligand)Cl] complexes, in which the ligand is a
biotinylated aminosulfonamide ligand, bound to streptavidin,
were used to catalyze the transfer hydrogenation of acetophe-
none and derivatives with formate as the hydrogen source,
giving rise to enantiomerically enriched 1-phenylethanols.[44]
The artificial metalloenzyme was optimized by saturation
mutagenesis at position S112. The highest enantioselectivities
were achieved by replacement of S112 by an aromatic amino
acid, such as Phe or Tyr; up to 97% ee of the R enan-
tiomer was obtained. It was proposed that attractive
CH/p interactions between the p-cymene ligand and
the aromatic ketone substrate are important for the
enantioselectivity. Interestingly, mutants containing a
cationic residue at position 112, such as S112K or
S112R produced the S enantiomer in up to 70% ee.[45]
Based on the crystal structure of the [h6-ben-
zene)Ru(biotinylated ligand)]/Sav S112 artificial metal-
loenzyme, positions K121 and L124 were selected for
further mutagenesis studies. A screening protocol
involving immobilization of the artificial metallo-
enzymes on biotin sepharose was used to facilitate
the optimization study. Using either the S112AK121N
or the S112AK121T mutant, excellent enantioselectiv-
ities were obtained for a broad range of methyl alkyl and
methyl aryl ketones. Surprisingly, it was found that the h6-coor-
dinated arene ligand is important in determining which mirror
image of the product is obtained in excess, with benzene and
p-cymene giving rise to the formation of opposite
enantiomers.[28]
3.2. Oxidations
Mn–salen complexes are some of the most powerful catalysts
for oxidation reactions.[46] By incorporation of Mn–salen com-
plexes into apo-Myoglobin, artificial metalloenzymes capable
of moderately enantioselective sulfoxidation using H2O2 as
terminal oxidant, have been reported. Using noncovalent an-
choring of the metal complex, up to 32% ee was obtained for
the S enantiomer.[16,47] Using the related Cr complex, 33% was
achieved. Alternative designs of the salen ligand have been
investigated, which resulted in an increase of the stability of
the artificial protein.[48] However, no catalysis was reported
with these variants. Covalent anchoring of the Mn–salen cofac-
tor, using a dual point attachment strategy, provided higher
enantioselectivities ; up to 51% ee was obtained.[49] Interesting-
ly, the R sulfoxide product was now obtained as the major
enantiomer. By changing one of the attachment sites in the
protein, the ee value could be increased to 60% (Scheme 4).[50]
Moreover, this artificial metalloenzyme displayed complete
chemoselectivity towards the sulfoxide product ; no formation
of sulfone was detected. This was attributed to the relatively
apolar nature of the active site, which does not favor binding
of the sulfoxide. As a result, overoxidation does not occur.
In a related design involving supramolecular anchoring of
the Mn–salen complex, the selectivity was also found to be pH
dependent.[51] At a pH of 6.4, an ee value of 67% was obtained.
At higher pH, the rate of sulfoxidation increased significantly,
albeit accompanied by a decrease in ee. Moreover, at this pH,
the artificial metalloenzyme is also capable of oxidizing 2,2’-azi-
nobis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS), something
it does not do at lower pH values, which suggests the involve-
ment of a different oxidizing intermediate. A crucial role was
identified for the distal hystidine ligand, which is involved in
the binding, orientation, and activation of the metal bound
H2O2 by hydrogen bonding interactions.
Scheme 3. Enantioselective transfer hydrogenations by an artificial
ruthenium enzyme based on streptavidin.
Scheme 4. a) Enantioselective and chemoselective sulfoxidations catalyzed by apo-Mb/
Mn–salen; b) Schematic representation of the protein bound Mn–salen complex.
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Serum albumins have emerged as one of the preferred scaf-
folds for the design of artificial metallo-oxygenases. In an early
report, bovine serum albumin conjugated with OsO4 gave rise
to an intriguing 68% ee in the dihydroxylation of alkenes,
using tBuOOH as terminal oxidant.[15] Fe and Mn corroles
bound noncovalently to serum albumins from various sources
have been used in enantioselective sulfoxidation reactions.[29]
Mn-corroles proved to be particularly effective; up to 74% ee
was obtained in the sulfoxidation of thioanisole derivatives
with H2O2. Mn–salen complexes have also been anchored non-
covalently to human serum albumin (HSA). Using NaOCl as the
terminal oxidant, chemoselective oxidation to the sulfone was
achieved, whereas in the absence of HSA the sulfone was the
major product. As with the Mn–salen/myoglobin system
described, the chemoselectivity was proposed to be related to
the unfavorable binding of the polar sulfoxide into the
relatively apolar binding pocket.[52]
Inspired by the vanadium haloperoxidases, which are cap-
able of enantioselective sulfoxidation reactions using H2O2,
[53]
artificial vanadium enzymes have been prepared by anchoring
of vanadate (VO4)
3 to phytase, giving rise to the chiral sulfox-
ide product with up to 66% of the S enantiomer.[54] Recently, a
streptavidin-based artificial vanadium enzyme was created by
addition of VOSO4. It is believed that the pentahydrated
vanadyl ion [VO(H2O)5]
2+ is bound in the binding pocket using
weak second coordination sphere contacts (Scheme 5). Excel-
lent ee values of up to 93%
were obtained in the sulfoxida-
tion of broad range thioanisole
derivatives and dialkyl sulfides.[55]
Streptavidin has also been
used in combination with biotin
linked Mn–salen complexes.[21]
However, to date, only low
enantioselectivities in catalytic
sulfoxidations were found using
tBuOOH.[56]
By substitution of the active
site Zn of carbonic anhydrase
with Mn2+ , an artificial perox-
idase enzyme was created.[20] Moderate enantioselectivities
were obtained in the epoxidation of various alkenes. An impor-
tant role for the amino alcohol buffer, for example tris(hydroxy-
methyl)aminomethane (Tris), was found; this buffer can bind in
the active site, thus reducing the space and limiting the way in
which a substrate such as styrene can bind. A mechanistic
proposal involving the formation of peroxycarbonates was put
forward. In a similar approach, moderate ee values were ob-
tained for a variety of alkene substrates.[57] It was shown that a
mutation of an active site (threonine to alanine), significantly
increased epoxidation yields, albeit that this mutation did not
give rise to improved enantioselectivity.
Artificial Fe hemoenzymes have been created by anchoring
an iron porphyrin to an anti-estradiol antibody, via a porphy-
rin-bound estradiol moiety,[58] or by supramolecular binding to
the enzyme xylanase A.[59] Only with the latter system were
significant enantioselectivities, up to 40%, obtained in the
sulfoxidation of thioanisole.
3.3. Lewis acid-catalyzed CC bond forming reactions
The concept of DNA-based asymmetric catalysis has mainly
found applications in enantioselective Lewis acid-catalyzed C
C bond forming reactions. In this concept, a new active site is
created on a salmon testes DNA (st-DNA) scaffold by noncova-
lent anchoring of an achiral CuII complex to the DNA double
helix by intercalation and/or groove binding. The proximity of
the catalytic center to the chiral DNA structure allows for trans-
fer of the chirality to the catalyzed reaction (Scheme 6). Proof
of principle for this concept was demonstrated in the CuII-cata-
lyzed Diels–Alder reaction of azachalcone with cyclopentadiene
in water.[22,60] Using a ligand comprising a 9-aminoacridine
moiety, a strong DNA intercalator, that is connected by a
spacer to an aminomethyl pyridine CuII binding moiety,
moderate ee values in the Diels–Alder product were obtained.
In an improved design, ligands that integrate the DNA and
metal binding moiety were employed, which eliminates the
spacer and allows for placing the active CuII center closer to
the DNA. The highest enantioselectivities were obtained with
2,2’-bipyridine ligands and in particular 4,4’-dimethyl-2,2’-bipyr-
idine (dmbipy): >99% ee of the endo isomer was obtained.[61]
Interestingly, the Cu–dmbipy complex has only a moderate
Scheme 5. Representation of the VOSO4/streptavidin artificial metalloenzyme
and enantioselective sulfoxidation.
Scheme 6. Representation of the DNA-based asymmetric catalysis concept.
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binding affinity for DNA, which means that under catalytic
concentrations not all the Cu–dmbipy is bound to the DNA.
Moreover, no apparent sequence selectivity for binding to
DNA was detected. This means that the DNA-based catalyst is
actually a heterogeneous mixture of Cu complexes that all
reside in a different microenvironment. Yet, despite this,
>99% ee could be achieved for multiple substrates.
In a kinetic study, the reaction in the presence of DNA
proved to be 58-fold faster than the reaction of Cu–dmbipy
alone.[27] It was also observed that the reaction was strongly
DNA-sequence dependent, with the best ee values obtained
for sequences containing tracts of three guanines. Importantly,
the DNA sequences that gave rise to the highest ee values,
also caused the largest rate accelerations. Combined, these re-
sults explain why DNA-based asymmetric catalysis works with
a heterogeneous scaffold such as st-DNA: the DNA accelerates
the reaction significantly, which means that unbound Cu–
dmbipy does not contribute significantly to the catalysis, and
the Cu–dmbipy complexes that are bound to DNA sequences
that cause the highest ee values, also give rise to the largest
rate accelerations and, hence, dominate the outcome of the
catalytic reaction. In other words, the enantioselectivities in-
duced by st-DNA are the weighted average of all contributing
DNA sequences.
In CuII-catalyzed reactions, usually bidentate binding of the
substrate is required.[62] However, from a synthetic perspective,
aza-chalcones are not particularly interesting substrates. The
introduction of a,b-unsaturated 2-acyl imidazoles as an alterna-
tive class of substrates,[63] allowed a significant expansion of
the scope of the DNA-based catalysis concept (Scheme 7). Ini-
tially, these substrates were evaluated in the enantioselective
Diels–Alder reaction, where similar ee values were found
compared to the reactions with aza-chalcone.[64] The substrate
scope of these reactions was quite broad and after the reac-
tion, the N-methyl imidazole moiety was displaced readily,
which allowed for determination of the absolute configuration
of the product.
These substrates also proved to be suitable electrophiles in
conjugate addition reactions catalyzed by st-DNA/Cu–dmbipy.
Using dimethyl malonate or nitromethane as the Michael
donors, the corresponding Michael addition products were ob-
tained with excellent enantioselectivities.[65] Again, the scope
of enone substrates accepted proved to be very broad. Using
neutral p-nucleophiles, such as indoles or pyrrole, the conju-
gate addition products were obtained in up to 93% ee.[66]
These reactions represent the first examples of catalytic
enantioselective vinologous Friedel–Crafts alkylations in water,
reactions that are typically associated with strictly anhydrous
conditions. In addition, in this case a significant DNA-accelera-
tion of up to 30-fold was observed. Interestingly, in all st-DNA/
Cu–dmbipy-catalyzed CC bond forming reactions, the
stereochemistry was predictable ; in every case the enantiomer
resulting from attack of the diene or nucleophile from the
same p-face was found in excess.
The CuII-catalyzed Diels–Alder reaction of aza-chalcone with
cyclopentadiene has also been used as the benchmark reac-
tion for a DNA-based catalyst containing a covalently attached
copper complex. Using a synthetic DNA that incorporates a
polyaza crown ether capable of binding CuII as a nucleotide
substitute, a low enantioselectivity was obtained.[67]
A modular assembly strategy towards covalently anchored
DNA-based catalysts has been introduced recently.[68] In this
approach a Cu-(2,2’-bipyridine) complex was linked covalently
to the 3’ or 5’ terminus of an oligonucleotide containing a ter-
minal amino linker. These modified oligonucleotides are readily
available from commercial sources. Combination of the bipy-
linked oligonucleotide with another oligonucleotide
and a template strand that is complementary to both
allowed for assembly of a duplex that contains the
bipyridine ligand internally at the interface between
the two oligonucleotides. The corresponding CuII
complex was evaluated in the Diels–Alder reaction of
aza-chalcone with cyclopentadiene. Depending of
the nucleotides flanking the covalently bound CuII
complex, up to 93% ee was obtained for the Diels–
Alder product.
Enantioselective Lewis acid-catalyzed reactions are
not limited to DNA scaffolds. BSA has been used as
source of chirality in Diels–Alder reactions in the ab-
sence of transition metal catalysts, resulting in ee
values of up to 38%.[69] By anchoring a copper phtha-
locyanine complex to BSA through a combination of
dative and supramolecular interactions, Reetz et al.
created a highly enantioselective artificial metalloen-
zyme that gave rise to ee values up to 98% in the
CuII-catalyzed Diels–Alder reaction of aza-chalcone
with cyclopentadiene.[70]
Incorporation of a non-proteinogenic CuII binding
amino acid into the peptide hormone bPP provided
an artificial copper enzyme capable of enantioselec-Scheme 7. Scope of the CC bond forming reactions catalyzed by st-DNA/Cu–dmbipy.
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tive Diels–Alder and Michael additions (Scheme 8).[23] Native
bPP exists as a dimer in solution and Tyr7, which is located at
the dimer interface, was replaced by 3-pyridylalanine, using
solid phase peptide synthesis. In the absence and presence of
CuII, the resulting bPP variant (bPPx) proved to be a mixture of
monomer and dimer, with the monomer being favored. It was
found that this artificial metalloenzyme displayed a high sub-
strate specificity. In case of the Diels–Alder reaction of aza-chal-
cones or a,b-unsaturated 2-acyl imidazoles with cyclopenta-
diene, the highest ee values, that is, up to 83%, were found for
R’=phenyl. With larger substituents, there was a significant
loss of activity and selectivity, whereas with a smaller substitu-
ent R’, such as R’=CH3, the activity was restored, but the reac-
tion was no longer enantioselective. In contrast, in the Michael
addition of these substrates with dimethyl malonate, a good
enantioselectivity of 86% was found for this substrate, whereas
with R’=phenyl hardly any activity and no enantioselectivity
was obtained. It was proposed that the active site provided by
this artificial metalloenzyme was structurally compatible with
certain substrate/reactant combinations only. Incompatibility
with the structure of the active site resulted in loss of activity
and/or enantioselectivity.
3.4. Allylic alkylations and aminations
Artificial metalloenzymes catalyzing organometallic CC and
CN bond forming reactions have been discovered recently.
Catalytic asymmetric allylic alkylation has been achieved using
the biotin/streptavidin system.[71] A PdII complex of a biotinylat-
ed ligand was anchored to (strept)avidin; the resulting artificial
palladium enzyme was evaluated in the allylic alkylation of 1,3-
diphenylallylacetate, using dimethyl malonate as the nucleo-
phile. Initial results showed only low reactivity towards the de-
sired product ; instead hydrolysis of the 1,3-diphenylallylacetate
occurred. Upon addition of a surfactant, that is, didodecyl-
dimethylammonium bromide (DMB), the yield of the allylic
alkylation product increased significantly. Starting from this ini-
tial design, using a chemogenetic optimization procedure, ex-
cellent ee values and conversions could be achieved. A key
aspect in the design proved to be the nature of the amino
acid spacer between the diphosphine ligand and the biotin
moiety, with the highest enantioselectivities obtained in case
of an o-aminobenzoate spacer: up to 93% ee was achieved
using an S112A streptavidin mutant. The 31% ee of the other
enantiomer of the product was obtained when a streptavidin
variant containing a S112Q mutation was used. Using a con-
strained amino acid spacer such as (S)-proline (Pro) or (S)-Pip
also gave rise to good ee values (Scheme 9). By using the R
enantiomer of these spacers, the opposite enantiomer of the
product could be obtained. In the absence of streptavidin,
only low to moderate ee values were obtained, underlining
that, even though the ligand is chiral, the presence of the
scaffold is important.
The group of Jschke reported the first DNA-based organo-
metallic catalyst.[72] A diene ligand was anchored covalently to
DNA. Hybridization with the complementary oligonucleotide
and coordination of an IrI salt gave rise to a DNA-based system
capable of catalyzing the allylic amination of phenyl allyl
acetate with morpholine (Scheme 9b). The enantioselectivities
were not high and were most likely related to the chiral diene
ligand. However, the enantiomeric outcome of the reaction,
that is, which enantiomer is obtained in excess, depended on
the nature and structure of the polynucleotide scaffold.
3.5. Miscellaneous
Two other enantioselective transformations have been report-
ed using DNA as the biomolecular scaffold. Enantioselective
electrophilic fluorination of indanone-based b-ketoesters using
selectfluor has been achieved using a st-DNA/Cu–dmbipy cata-
lyst. Depending on the structure of the b-ketoester substrate,
up to 74% was obtained.[73]
In addition, using st-DNA/Cu–dmbipy, the hydrolytic kinetic
resolution of pyridyloxiranes was reported. A low selectivity
factor (S=2.7) was found in case of trans-b-phenyl pyridyl-
oxirane. The selectivity proved to be structure dependent; no
Scheme 8. a) Enantioselective Diels–Alder and Michael addition reactions
catalyzed by Cu-bPPx ; b) representation of the monomer/dimer equilibrium
of bPPx ; c) a 3-pyridylalanine residue.
Scheme 9. a) Enantioselective allylic alkylation by an artificial palladium
enzyme based on streptavidin; b) DNA–Ir-catalyzed enantioselective allylic
amination.
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significant selectivity was observed in case of cis-b-phenyl
pyridyloxirane.[74]
4. The Role of the Second Coordination
Sphere
The field of artificial metalloenzymes was built on the promise
that the second coordination sphere provided by the biomo-
lecular scaffold would confer enzyme-like properties to transi-
tion metal catalysis. This would then result in a new branch of
catalysis in which the attractive properties of chemo- and bio-
catalysis could be merged, resulting in catalysis that combines
the best of both worlds. With the field maturing rapidly, it is a
good time to take stock and assess whether the field has lived
up to its expectations, to date. Herein, we provide an overview
of the role that the second coordination sphere of the biomo-
lecular scaffold plays in catalysis. Evaluation of the data avail-
able reveals a number of important parameters in a catalyzed
reaction that are affected by the biomolecular scaffold:
1) Reaction rate. The transition metal catalyst is principally
responsible for the catalysis and rate acceleration. But the rate
of the reaction is also affected by the presence of the biomo-
lecular scaffold. In some cases, the catalyzed reaction becomes
slower.[26,41,70] However, there are now many examples of artifi-
cial metalloenzymes in which the second coordination sphere
affects the rate positively, which is evident from the increased
conversions that were found for the artificial metalloenzyme
compared to the transition metal catalysts alone, and the
kinetic data.[27,49, 54,55,65, 66,71,75] The rate accelerations reported
range from a modest twofold increase, to up to two orders of
magnitude. Often these rate accelerations are substrate
dependent, which is consistent with an enzyme active site that
prefers binding of some substrates over others or that is com-
patible with certain activated complexes only. Obviously, rate
acceleration induced by the biomolecular scaffold is an attrac-
tive phenomenon from a catalytic perspective. However, in
particular when using supramolecular anchoring approaches, it
is also highly desirable since at low concentrations, the posi-
tion of the equilibrium between bound and unbound catalyst
can become unfavorable. This results in the presence of signifi-
cant amounts of unbound catalyst, which gives rise to the for-
mation of a racemic product, thus causing a lower overall ee.
As the case with DNA-based asymmetric catalysis,[27] this is not
a problem when the DNA-bound metal complex is significantly
faster than the unbound catalyst.
2) Chemoselectivity. The biomolecular scaffold determines
the chemical properties, such as the polarity of the microenvir-
onment around the incorporated transition metal complex
and, hence, can effect the chemoselectivity of a catalyzed reac-
tion. For example, in the sulfoxidation of thioanisole to the cor-
responding sulfoxide by a artificial metalloenzymes, such as
Mn–salen/apo-Mb[50] or Mn–salen/HAS,[52] the sulfoxide product
was obtained selectively; whereas in the absence of the bio-
molecular scaffold, significant amounts of sulfone also were
found. It was demonstrated that the relative apolar nature and
the proton donating capabilities of the environment surround-
ing the Mn–salen inside the protein disfavors binding of the
polar sulfoxide, and therefore, prevents overoxidation to the
sulfone.
3) Enantioselectivity. The chiral structure provided by the
biomolecular scaffold is used to generate reaction products in
an enantiomerically enriched form. As discussed earlier, many
examples of enantioselective catalysis with artificial metallo-
enzymes have been reported. In particular, the biotin/
(strept)avidin and the DNA-based catalysts have been effective
in multiple reaction classes with enantioselectivities of greater
than 90%. For many of these reactions, these enantio-
selectivities represent the highest that have been obtained for
reactions in aqueous solutions to date.
4) Size and shape selectivity. Many of the artificial metallo-
enzymes have a broad substrate scope, which is a typical char-
acteristic of chemocatalysis. In some cases, however, the bio-
molecular scaffold imposes restrictions on which substrates or
substrate/reactant combinations will be reactive. In case of the
Pd nanoparticles encapsulated in the protein cage ferritin, it
was shown that the size and structure of the pore allows
passage into the cage of certain substrates only.[26] Larger sub-
strates cannot reach the catalytic site and, as a result, are not
converted into product. In the case of Cu-bPP, which was
active in both the Diels–Alder reaction and the Michael addi-
tion reaction, it was found that this artificial metalloenzyme
displayed a high substrate specificity.[23] This was attributed to
the structure of the active site provided by this artificial metal-
loenzyme being compatible with certain substrate/reactant
combinations only. Incompatibility with the structure of the
active site results in loss of activity and/or enantioselectivity. In
this sense, this system resembles a true enzymatic catalyst,
which generally also has active sites that are compatible with
certain substrates only.
Often, several of these parameters are affected simultane-
ously by the biomolecular scaffold. For example, in many of
the reactions catalyzed by artificial metalloenzymes based on
the biotin/(strept)avidin system or the DNA-based asymmetric
catalysis concept, high enantioselectivities are often accompa-
nied by significant rate accelerations induced by the biomolec-
ular scaffold. These observations defy the conventional
wisdom in asymmetric homogeneous catalysis, which says that
enantioselectivity is usually achieved at the expense of activity.
5. Potential Application in Synthesis and
Outlook
To date, the field of artificial metalloenzymes has mainly
focused on the fundamental aspects of the design and the
catalysis. Only in a limited number of cases have artificial
metalloenzymes been applied in reactions on a preparative
scale. The DNA-based catalytic enantioselective Diels–Alder,
Michael addition, and Friedel–Crafts alkylation have all been
carried out on a preparative scale, that is, a mmol scale of sub-
strates, which corresponds to multiple hundreds of milligrams.
In all cases, good isolated yields of the products were obtained
with excellent enantioselectivities. It was found that after ex-
traction of the product from the aqueous phase, which still
contains the DNA-based catalyst, fresh reagents could be
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added and the reaction proceeded as efficient as before. Thus,
the catalyst was recycled multiple times without loss in isolat-
ed yields and enantioselectivity. Recently, it was reported that
significant amounts of organic cosolvents were tolerated by
the catalyst,[76] which allowed for the use of higher substrate
concentrations and lower temperatures. In this manner, the Mi-
chael addition and the Friedel–Crafts alkylation reactions were
carried out at a gram scale at 4 and 18 8C, respectively,
giving rise to excellent isolated yields and enantioselectivities.
In general, for artificial metalloenzymes to become attractive
for applications in synthesis and be competitive with conven-
tional catalysis approaches, a number of important conditions
are identified:
1) The biomolecular scaffold should be readily available in
large quantities at reasonable costs.
2) The artificial metalloenzyme should be straightforward to
assemble and easy to handle. In this respect, the supra-
molecular anchoring approaches are preferred since they rely
on self-assembly; covalent anchoring usually requires an
intermediate purification step, which is undesirable.
3) Scalability requires that low catalyst loadings can be used
in combination with high substrate concentrations to keep the
total reaction volume acceptable. Since the solubility of many
organic substrates in water is limited, the use of organic
cosolvents will be required in many cases, which should be
tolerated by the biomolecular scaffold.
Even if all the above criteria are met, most synthetic
chemists will most likely still be hesitant to use an artificial
metalloenzyme for their reactions. One important reason is
that for all enantioselective transformations reported to date,
good alternatives using conventional approaches, such as ho-
mogeneous or biocatalysis, are available. The main advantage
that artificial metalloenzymes offer from a synthetic perspec-
tive is that they allow for asymmetric catalysis in water as the
reaction medium. Indeed, many of the highly enantioselective
reactions reported, that is reactions giving >90% ee, represent
the best results that have been reported for asymmetric
catalysis in water, to date.
For the long term, however, it is imperative that the field of
artificial metalloenzymes starts to address some of the
challenges in enantioselective catalysis, for which there are no
solutions available in conventional asymmetric catalysis, there-
by making full use of the clear advantages that the second
coordination sphere has to offer. In view of the impressive
progress that has been achieved in this field in the last years,
it is expected that the field of artificial metalloenzymes will live
up to its promise and demonstrate that the best of both
worlds really can be achieved.
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